Publications by authors named "Thomas Hach"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

27,800

Total Likes

1,282

Extended Reach

5,258,845

Social Features

167
A
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy.
Vlado Perkovic, Jonathan Barratt, Brad Rovin, Naoki Kashihara, Bart Maes, Hong Zhang, Hernán Trimarchi, Dmitrij Kollins, Olympia Papachristofi, Severina Jacinto-Sanders

N Engl J Med· February 2025

Videos about Article: user user

2 3 3 162 4 1 7

View All Article and Social Media Activity
R
Rationale for Use of Sphingosine-1-Phosphate Receptor Modulators in COVID-19 Patients: Overview of Scientific Evidence.
Thomas Hach, Kasra Shakeri-Nejad, Marc Bigaud, Frank Dahlke, Massimiliano de Micco

J Interferon Cytokine Res· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers.
Lars Forsberg, Tim Spelman, Pernilla Klyve, Ali Manouchehrinia, Ryan Ramanujam, Thomas Hach

Mult Scler J Exp Transl Clin· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies.
Tjalf Ziemssen, Virender Bhan, Jeremy Chataway, Tanuja Chitnis, Bruce Anthony Campbell Cree, Thomas Hach

Neurol Neuroimmunol Neuroinflamm· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
Douglas L Arnold, Daniela Piani-Meier, Amit Bar-Or, Ralph Hb Benedict, Bruce Ac Cree, Thomas Hach

Mult Scler· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
Ralf Gold, Daniela Piani-Meier, Ludwig Kappos, Amit Bar-Or, Patrick Vermersch, Thomas Hach

J Neurol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcome measures in MS: Do development processes and patient involvement support valid quantification of clinically important variables?
Trishna Bharadia, Jo Vandercappellen, Tanuja Chitnis, Piet Eelen, Birgit Bauer, Thomas Hach

Mult Scler J Exp Transl Clin· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cryptococcal Meningitis Reported With Fingolimod Treatment: Case Series.
Maurizio Del Poeta, Brian J Ward, Benjamin Greenberg, Bernhard Hemmer, Bruce A C Cree, Thomas Hach

Neurol Neuroimmunol Neuroinflamm· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients: Case Series.
Roseanne Sullivan, Ajay Kilaru, Bernhard Hemmer, Bruce Anthony Campbell Cree, Benjamin M Greenberg, Thomas Hach

Neurol Neuroimmunol Neuroinflamm· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey.
Tjalf Ziemssen, Gavin Giovannoni, Enrique Alvarez, Virender Bhan, Carrie Hersh, Thomas Hach

J Med Internet Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement of long-term risks of cardiovascular events associated with community-based disease management in Chinese patients of the Xinjiang autonomous region of China.
Yang Li, Cai Minzhang, Ma Minghui, Huang Xinmiao, Liu Laixin, Thomas Hach

BMC Public Health· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study.
Tjalf Ziemssen, Daniela Piani-Meier, Bryan Bennett, Chloe Johnson, Katie Tinsley, Thomas Hach

J Med Internet Res· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Slope of change in HbA from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes.
Ralph A DeFronzo, Ele Ferrannini, Guntram Schernthaner, Stefan Hantel, Ulrich Elsasser, Thomas Hach

Endocrinol Diabetes Metab· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to: Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration.
Marko Škrtić, Gary K Yang, Bruce A Perkins, Nima Soleymanlou, Yuliya Lytvyn, Thomas Hach

Diabetologia· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials.
Kun-Ho Yoon, Rimei Nishimura, Jisoo Lee, Susanne Crowe, Afshin Salsali, Thomas Hach

Diabetes Obes Metab· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride.
Costel Chirila, Qingyao Zheng, Eric Davenport, Dagmar Kaschinski, Egon Pfarr, Thomas Hach

Qual Life Res· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.
Giulia Ferrannini, Thomas Hach, Susanne Crowe, Arjun Sanghvi, Kevin D Hall

Diabetes Care· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study.
Rimei Nishimura, Yuko Tanaka, Kazuki Koiwai, Kohei Inoue, Thomas Hach

Cardiovasc Diabetol· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration.
Marko Skrtić, Gary K Yang, Bruce A Perkins, Nima Soleymanlou, Yuliya Lytvyn, Thomas Hach

Diabetologia· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes.
Ele Ferrannini, Andreas Berk, Stefan Hantel, Sabine Pinnetti, Thomas Hach

Diabetes Care· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular effects of C-Peptide in microvascular blood flow regulation.
Thomas Forst, Thomas Hach, Thomas Kunt, Matthias M Weber, Andreas Pfützner

Rev Diabet Stud· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients.
Thomas Hach, Thomas Forst, Thomas Kunt, Karin Ekberg, Andreas Pfützner

Exp Diabetes Res· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis